ENGN · enGene Therapeutics Inc. · Analyst Estimates
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”View the 10-Q filed Jun 15, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for enGene Therapeutics Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians. An EPS figure names its accounting basis, GAAP or Non-GAAP, where the capture records one, and compares only with the company's EPS on that basis; without one, the basis is not recorded.
Captured 2026-11-14 05:29 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-10-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.89
|
-1.82
|
-1.73
|
8
|
-1.81
|
-1.81
|
-1.81
|
-1.73
|
6
|
6
|
2
|
2
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
8
|
— | — | — | — | — | — | — | — |
FY ending 2027-10-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.98
|
-1.59
|
-1.03
|
7
|
-1.51
|
-1.45
|
-1.44
|
-1.40
|
4
|
4
|
3
|
3
|
|
Revenue
USD
Publication date not stated |
0.00
|
4.68M
|
14.67M
|
7
|
— | — | — | — | — | — | — | — |
Q ending 2026-10-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.55
|
-0.47
|
-0.39
|
8
|
-0.46
|
-0.46
|
-0.46
|
-0.41
|
5
|
5
|
2
|
2
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
8
|
— | — | — | — | — | — | — | — |
Q ending 2027-01-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.44
|
-0.38
|
-0.30
|
3
|
-0.34
|
-0.34
|
-0.34
|
-0.31
|
3
|
3
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
4
|
— | — | — | — | — | — | — | — |